Physician profile
Birgit Toome
NPI 1891788121
$12,760.10
in general payments reported to CMS, 2019-2025
38 companies · $2,746 in 2025
The $2,746 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $860 · 2020: $690 · 2021: $1,296 · 2022: $2,129 · 2023: $2,344 · 2024: $2,694 · 2025: $2,746.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,489 · Education: $296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,488.89 |
| Education | $296.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $1,915.37 | 2019-2025 | |
| Abbvie INC. | $1,842.16 | 2019-2025 | Skyrizi, Rinvoq, Humira |
| Leo Pharma INC. | $912.84 | 2019-2025 | Adbry, Anzupgo |
| Novartis Pharmaceuticals Corporation | $851.42 | 2019-2025 | |
| Lilly USA, LLC | $772.07 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Ucb, INC. | $639.22 | 2019-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $527.51 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $490.27 | 2019-2025 | Siliq, Arazlo, Cabtreo |
| Arcutis Biotherapeutics, INC. | $457.83 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $439.40 | 2022-2025 | Tremfya |
| Pfizer INC. | $419.00 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $408.16 | 2019-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $396.92 | 2019-2025 | Winlevi, Ilumya |
| Merz North America, INC. | $354.87 | 2019-2020 | |
| Galderma Laboratories, L.P. | $347.35 | 2019-2025 | Nemluvio, Aklief, Epsolay |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $309.84 | 2019-2024 | |
| Amgen INC. | $256.91 | 2020-2025 | Otezla, Otezla |
| Almirall LLC | $233.69 | 2022-2025 | Seysara |
| Dermavant Sciences, INC. | $202.11 | 2023-2024 | Vtama |
| Genentech USA, INC. | $121.19 | 2022-2024 | Erivedge |
| Dermira, INC. | $113.61 | 2020-2021 | |
| Epi Health, LLC | $110.47 | 2019-2022 | |
| Strata Skin Sciences, INC. | $86.13 | 2023-2025 | Xtrac |
| Journey Medical Corporation | $83.70 | 2019-2023 | |
| Sebela Pharmaceuticals INC. | $53.56 | 2020-2023 | Naftin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.35 | 2023-2024 | Spevigo, Cyltezo |
| Verrica Pharmaceuticals INC. | $50.71 | 2024 | Ycanth |
| Organon LLC | $49.64 | 2025 | Vtama |
| Allergan, INC. | $40.60 | 2020-2022 | |
| Vyne Pharmaceuticals INC. | $39.59 | 2021 | |
| Botanix Sb INC | $33.72 | 2025 | Sofdra |
| Kerecis Limited | $32.70 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Biofrontera INC. | $28.74 | 2021 | |
| Smith+Nephew, INC. | $24.61 | 2023 | Grafix, Grafix Pl |
| Blueprint Medicines Corporation | $19.45 | 2023 | |
| Krystal Biotech INC | $16.22 | 2025 | Vyjuvek |
| Mission Pharmacal Company | $14.91 | 2022 | |
| Sandoz INC. | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Birgit Toome listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.